首页|PCSK9抑制药的药理作用机制研究现状及临床应用探讨

PCSK9抑制药的药理作用机制研究现状及临床应用探讨

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
由脂质代谢紊乱引起的动脉粥样硬化是动脉粥样硬化性心血管疾病的主要病理基础.他汀类药物是这类疾病调脂治疗的基石,但在实际应用中部分患者仍存在血脂管理不达标的状况.前蛋白转化酶枯草溶菌素9(PCSK9)抑制药作为一类新型调脂药物被逐渐应用于该类患者治疗,近年来的研究表明PCSK9抑制药除了能调节脂质代谢,还具有潜在的抗炎、抗血小板活化等作用.本文梳理了 PCSK9抑制药多个药理作用机制及临床研究现状,探讨可能影响PCSK9抑制药疗效的因素,以期为PCSK9抑制药的安全合理用药提供参考.
Research status of pharmacological mechanism of PCSK9 inhibitors and discussion of their clinical application
Atherosclerosis caused by disorders of lipid metabolism is the main pathological basis of atherosclerotic cardiovascular disease.Statins are the cornerstone of lipid-modulating therapy for this type of disease,but in practice there are still some patients with suboptimal lipid management.Proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors have been gradually applied as a new class of lipid-modulating drugs for the treatment in patients with this type of disease,and recent studies have shown that in addition to regulating lipid metabolism,PCSK9 inhibitors also have potential anti-inflammatory and anti-platelet activation effects.This article sorts out the multiple pharmacological mechanisms of action of PCSK9 inhibitors and the current status of clinical research of PCSK9 inhibitors.Besides,it discusses the factors that may affect the efficacy of PCSK9 inhibitors,in order to provide a reference for the safe and rational medication of PCSK9 inhibitors.

Proprotein convertase subtilisin/kexin type 9 inhibitorsatherosclerotic cardiovascular diseasemechanism of actionapplication status

莫文慧、徐思蕾、何霞、白妞妞、袁梦莹、李志敏、张娇、王菲、郑湲坤

展开 >

四川省医学科学院·四川省人民医院药学部,四川成都 610072

电子科技大学医学院个体化药物治疗四川省重点实验室,四川成都 610054

山西医科大学药学院,山西太原 030001

重庆市红十字会医院(江北区人民医院)药学部,重庆 400020

展开 >

前蛋白转化酶枯草溶菌素9抑制药 动脉粥样硬化性心血管疾病 作用机制 应用现状

四川省科技厅重点研发课题个体化药物治疗四川省重点实验室开放基金个体化药物治疗四川省重点实验室开放基金

2022YFS02722021ZD022022YB02

2024

10.13699/j.cnki.1001-6821.2024.16.029

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子：1.91
ISSN：1001-6821
年,卷(期)：2024.40(16)
  • 1